

MPP prioritised and watchlist products

MARCH 2025

 **HIV**

cabotegravir LA

ViiV

lenacapavir

Gilead

MK-8527

MSD

islatravir

MSD

GS-1720

Gilead

GS-4182

Gilead

cabotegravir 4-monthly

ViiV

doravirine

MSD

TAF/EVG insert

Conrad

ulonivirine

MSD

VH4524184

ViiV

VH4011499

ViiV

 **PANDEMIC & EPIDEMIC THREATS**

baloxavir marboxil

Roche

 **TUBERCULOSIS**

quabodepistat

Otsuka

alpipectir

GSK

bedaquiline long-acting

Janssen

delpazolid

LegoChem BioSciences

ganfeborole


GSK

macozinone

EPFL

sudapyridine

Shanghai Jiatan Biotech

 **VIRAL HEPATITIS**

HEPATITIS C

bemnifosbuvir

Atea

ruzasvir

Atea

HEPATITIS B

bepirovirsen

GSK

 **FOCUS ON CHILDREN**

RESPIRATORY SYNCYTIAL VIRUS

nirsevimab

AstraZeneca/ Sanofi

clesrovimab

MSD

MALARIA

MicroCoat AS/AQ

FluidPharma

LOW-GRADE GLIOMAS

dabrafenib/trametinib

Novartis

CYSTIC FIBROSIS

elexacaftor/ivacaftor/tezacaftor

Vertex

HIV POST-NATAL PROPHYLAXIS

Monoclonal antibodies

Multiple innovators

 **ONCOLOGY**

MULTIPLE CANCER INDICATIONS

Immune checkpoint inhibitors

including Multiple innovators

pembrolizumab

MSD

LUNG CANCER

aumolertinib

Hansoh Pharma

osimertinib

Astrazeneca

adagrasib

Mirati

lazertinib

Janssen

sotorasib

Amgen

BREAST CANCER

abemaciclib

Eli Lilly

ribociclib

Novartis

trastuzumab SQ

Roche

CHRONIC LYMPHOCYTIC LEUKAEMIA

zanubrutinib

Beigene

PROSTATE CANCER

apalutamide

Janssen

darolutamide

Bayer

 **DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS**

Incretin-based therapies (incl. GLP1 RA)

Multiple innovators

including

semaglutide

Novo Nordisk

tirzepatide

Eli Lilly

orforglipron

Eli Lilly

retatrutide

Eli Lilly

Insulin analogues

Multiple innovators

cardiovascular fixed-dose combination therapies

Multiple innovators

PRIORITY LIST

WATCHLIST